ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Clinical trial NCT03338816 · COMPLETED

Trial details

NCT number: NCT03338816
Sponsor: Alnylam Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Hepatic Porphyria Acute Intermittent Porphyria Porphyria, Acute Intermittent Acute Porphyria Hereditary Coproporphyria (HCP)Variegate Porphyria (VP)ALA Dehydratase Deficient Porphyria (ADP)

Start date: 2017-11-16
Primary completion: 2019-01-31
Enrollment: 94

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.